Wockhardt Limited shareholders have overwhelmingly approved the appointment of Om Prakash Bhatt as Non-Executive Independent Director for a five-year term through a postal ballot. The company announced that 99.99% of votes were cast in favor of the appointment, with the scrutinizer's report officially confirming the results.

Appointment Details and Term

The special resolution approved Mr. Om Prakash Bhatt's appointment with Director Identification Number (DIN) 00548091 for a comprehensive five-year term. The appointment specifics are outlined below:

Voting Results and Participation

The postal ballot demonstrated strong shareholder support across all categories. The e-voting process recorded exceptional participation and approval rates with 770 shareholders participating out of 144,639 total shareholders on record.

Overall Voting Statistics

Category-wise Voting Breakdown

The voting results showed unanimous support across different shareholder categories:

Voting Process and Compliance

The postal ballot was conducted in accordance with Section 110 of the Companies Act, 2013, and the Companies (Management and Administration) Rules, 2014. The remote e-voting facility was provided through National Securities Depository Limited (NSDL) platform, ensuring secure and transparent participation.

Key process highlights included:

• Record Date: November 7, 2025
• E-voting Period: November 15, 2025 to December 14, 2025
• Notice Distribution: Electronic mode only to registered email addresses
• Newspaper Publication: Business Standard (English) and Lokmat (Marathi) on November 15, 2025

Scrutinizer Report and Validation

Mr. Virendra G. Bhatt, Practicing Company Secretary (ACS No. 1157), served as the appointed scrutinizer for the postal ballot process. His report confirmed the validity and fairness of the voting procedure, with all electronic data and relevant records maintained under safe custody. The scrutinizer's report was issued on December 15, 2025, validating the overwhelming shareholder approval for the resolution.

The e-voting process concluded at 5:00 p.m. on December 14, 2025, and the votes were unblocked in the presence of two independent witnesses, Ms. Khushi Gangwal and Mr. Sahil Pawar, who are not in the employment of the company or NSDL. The appointment strengthens Wockhardt's board composition with an experienced independent director, reflecting strong shareholder confidence in the company's governance structure and strategic direction.

Wockhardt Ltd , a prominent Indian pharmaceutical company, has achieved a significant milestone in the global pharmaceutical industry. The company recently received approval from the US Food and Drug Administration (FDA) for its New Drug Application (NDA) for Zaynich, an antibiotic developed to address urgent medical needs.

Breakthrough for Indian Pharma

This approval marks a historic moment for the Indian pharmaceutical sector, as Wockhardt becomes the first Indian company to receive an NDA approval from the US FDA. This achievement underscores the growing capabilities and innovation within India's pharmaceutical industry on the global stage.

Fast-Track Status

The FDA granted Zaynich a fast-track status, highlighting the antibiotic's potential to fulfill critical medical requirements. This expedited review process is typically reserved for drugs that show promise in treating serious conditions and addressing unmet medical needs.

Regulatory Significance

The approval of Zaynich represents a major regulatory milestone for Wockhardt. It demonstrates the company's ability to navigate the stringent approval processes of the US FDA, which is known for its high standards in drug safety and efficacy.

Potential Impact

While specific financial implications are not available at this time, the approval of Zaynich could potentially open new market opportunities for Wockhardt in the United States, one of the world's largest pharmaceutical markets. The successful development and approval of a novel antibiotic also positions Wockhardt as an innovator in addressing global health challenges, particularly in the fight against antibiotic-resistant infections.

As the pharmaceutical landscape continues to evolve, Wockhardt's achievement with Zaynich may pave the way for more Indian companies to pursue and obtain FDA approvals for their innovative drug candidates.